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Research Article
Variants of the human PPARG locus and
the susceptibility to chronic periodontitis
Matthias Folwaczny1, Vasilios Manolis1, Christian Markus2 and
Ju¨rgen Glas1,3
Abstract
Apart from its regulatory function in lipid and glucose metabolism, peroxisome proliferator-activated receptor (PPAR)g
has impact on the regulation of inflammation and bone metabolism. The aim of the study was to investigate the asso-
ciation of five polymorphisms (rs10865710, rs2067819, rs3892175, rs1801282, rs3856806) within the PPARG gene with
chronic periodontitis. The study population comprised 402 periodontitis patients and 793 healthy individuals. Genotyping
of the PPARG gene polymorphisms was performed by PCR and melting curve analysis. Comparison of frequency distri-
bution of genotypes between individuals with periodontal disease and healthy controls for the polymorphism rs3856806
showed a P-value of 0.04 but failed to reach significance after correction for multiple testing (P< 0.01). Two single
nucleotide polymorphisms (SNPs) (rs10865710 and rs3892175) were found to be in strong linkage disequilibrium to
rs2067819 (D’> 0.90). A 3-site analysis (rs2067819-rs1801282-rs3856860) revealed five haplotypes with a frequency of
1% among cases and controls. Following adjustment for age, gender and smoking, none of the haplotypes was signif-
icantly different between periodontitis and healthy controls after Bonferroni correction. This study could not show a
significant association between PPARG gene variants and chronic periodontitis.
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Introduction
Periodontal disease is defined as a bacterial-derived
chronic infection of the gingival crevicular area.1,2
In order to explain the considerable discrepancies in
individual host susceptibility, a strong genetic back-
ground for the pathogenesis of chronic periodontitis
has been suggested. A previous study on twins esti-
mated that the heritability of this entity reaches even
50%.3 According to a common pathogenetic model, the
genetic impact on individual susceptibility and/or sever-
ity of periodontitis are mediated by either an inappro-
priate or exaggerated immune response against a given
bacterial stimulus.4,5 Hence, polymorphisms of genes
that are involved in the stimulation and regulation of
inflammatory processes are excellent candidates for the
elucidation of the genetic background of the periodon-
tal pathogenesis.6
The peroxisome proliferator-activated receptors
(PPARs) are members of the nuclear receptor super-
family and are ligand activated transcription factors
(for review, see Rizzo et al.7). Three subtypes have
been identified so far: PPARa (NR1C1), PPARb/d
(NR1C2) and PPARg (NR1C3). The PPARs are
activated by different natural ligands, i.e. fatty acids,
eicosanoids, and oxidized fatty acids, as well as
by lipid-lowering fibrates and the anti-diabetic
glitazones.8,9
The PPARs are primarily involved in lipid and
lipoprotein metabolism, glucose homeostasis, cell pro-
liferation and differentiation.10 Moreover, a growing
body of evidence suggests that at least PPARg plays
a significant role in regulation and mediation of
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inflammatory reactions.11 Particularly, PPARg influ-
ences the differentiation of monocytes and attenuates
the expression of various pro-inflammatory mediators
(e.g. TNF-a, IL-1b and IL-6).12–14 Also matrix metal-
loproteinase (MMP) 9, which is involved in periodontal
inflammatory process, is down-regulated by PPARg.14
Various polymorphisms at the human PPARG locus
have yet been described. It has been suggested that
some of these variants (rs10865710, rs2067819,
rs3892175, rs1801282, rs3856806) might be functionally
effective, particularly leading to impaired anti-inflam-
matory effects of PPARg.15–17 For instance, the vari-
ants rs1801282 and rs10865710 were shown to be
associated with the risk of myocardial infarction18
and with systemic levels of inflammatory markers in
patients with end-stage renal disease.19
The present study aimed to assess whether these
polymorphisms of the PPARG gene contribute to the
susceptibility for periodontal disease.
Subjects and methods
Patient population
Individuals with severe medical disorders including dia-
betes mellitus, immunological disorders, increased risk
for bacterial endocarditis and pregnant females were
excluded from the study. The study conformed to the
ethical guidelines of the Helsinki Declaration and was
approved by the local ethics committee. Participants
provided written, informed consent prior to their
enrolment into the study. Study subjects in both
groups were adult, unrelated Caucasians from the
south of Germany (region of Upper Bavaria).
In order to improve genetic homogenicity of the study
sample, all subjects must have parents and grandpar-
ents of the German ethnic group.
Subjects in both study groups received a standard-
ized periodontal examination protocol including the
evaluation of: (i) the probing pocket depth measured
at six locations on each tooth (mesio-buccal, mid-
buccal, disto-buccal, mesio-lingual, mid-lingual, disto-
lingual) using a Michigan type ‘O’ probe; (ii) furcation
involvement using a Naber type probe; (iii) bleeding on
probing registered as present or absent; and (iv) bone
loss as assessed by orthopantomographs. The probing
pocket depth was defined as the distance from the free
gingival margin to the base of the periodontal pocket
keeping the probe in line with the long axis of the tooth.
For the examination of furcation defects, horizontal
probing from the furcation entrance to the base of
the defect was used. The furcation involvement was
classified according to the protocol of Nyman and
Lindhe.20 Due to ethical reasons, radiographic exami-
nation using orthopantomographs was done for indi-
viduals having periodontitis only.
A total of 402 patients from the Department of
Periodontology, Ludwig-Maximilians University
(Munich, Germany) were enrolled. The median age in
the periodontitis group was 54.1 years (SD 10.9) and
the age ranged from 18–85 years (Table 1).
The patients fulfilled the following clinical criteria:
(i) a total of at least 15 teeth in situ; (ii) 8 teeth with a
probing pocket depth of 5mm at least at one location
and/or a furcation involvement class II; and (iii) evi-
dence of bone loss manifested as the distance between
the alveolar crest and the cemento-enamel junction of
3mm around the affected teeth.
A total of 793 unrelated, ethnically matched,
Caucasian individuals without periodontitis comprised
the healthy control group. The absence of periodontal
disease was determined according to the following cri-
teria: (i) a minimum of 22 teeth in situ; (ii) 1 site with
probing pocket depth 3mm; and (iii) lack of any kind
of furcation involvement at any tooth. Within the con-
trol group, the median age was 47.3 years (SD 9.2)
and the age ranged from 18– 73 years.
Information regarding smoking habit was available
for 354 of the patients with periodontitis and 538 of the
control persons. Individuals have been classified as
smokers if they had a self-reported history of smoking
of at least 10 cigarettes/day for at least one year.
Blood samples and DNA isolation
Peripheral venous blood samples of 9ml were drawn
from each individual by standard venepuncture. Each
blood sample was collected in sterile tubes containing
K3EDTA solution. DNA was isolated using partly the
QIAamp DNA Blood Midi Kit (Qiagen, Hilden,
Germany), partly the salting out procedure.21
Table 1. Demographic data of the two study groups with
periodontitis patients and healthy individuals
Control Periodontitis
P-value(n¼ 793) (n¼ 402)
Age at diagnosis
years (mean)
8–73 (47.3) 21–85 (54.1) 0.001
Sex
Male (%) 531 (67.4) 178 (47.5)
Female (%) 257 (32.6) 197 (52.5) 0.001
Smoking
Smokers (%) 67 (12.5) 113 (31.9)
Non-smokers (%) 471 (87.5) 241 (68.1) 0.001
Number of teeth ND 25.3 (4.9)
Cases per severity
Mild ND 86 (37.4)
Moderate ND 81 (35.2)
Severe ND 63 (27.4)
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Genotyping of the polymorphisms within the
PPARG gene
Five PPARG single nucleotide polymorphisms (SNPs)
(rs10865710, rs2067819, rs3892175, rs1801282,
rs3856806) were genotyped partly by PCR and restric-
tion fragment length polymorphism (RFLP) analysis as
described elsewhere22 and partly by PCR and melting
curve analysis using a pair of fluorescence resonance
energy transfer (FRET) probes in a LightCycler 480
Instrument (Roche Diagnostics, Mannheim,
Germany). The donor fluorescent molecule (fluorescein)
at the 3’-end of the sensor probe is excited at its specific
fluorescence excitation wavelength (533 nm) and the
energy is transferred to the acceptor fluorescent mole-
cule at the 5’-end (LightCycler Red 610, 640 or 670) of
the anchor probe. The specific fluorescence signal emit-
ted by the acceptor molecule is detected by the optical
unit of the LightCycler 480 Instrument. The sensor
probe is exactly matching to one allele of each SNP,
preferentially to the rarer allele, whereas in the case of
the other allele there is a mismatch resulting in a lower
melting temperature. The total volume of the PCR was
5 ml containing 25 ng of genomic DNA, 1Light Cycler
480 Genotyping Master (Roche Diagnostics), 2.5 pmol
of each primer and 0.75 pmol of each FRET probe (TIB
MOLBIOL, Berlin, Germany). In the case of
rs10865710, the concentration of the forward primer
was reduced to 1.25 pmol. The PCR comprised an initial
denaturation step (95C for 10min) and 45 cycles (95C
for 10C s, primer annealing temperature as given in
supplementary material (Table S1) for 10 s, 72C for
15 s). The melting curve analysis comprised an initial
denaturation step (95C for 1min), a step rapidly low-
ering the temperature to 40C and holding for 2min, and
a heating step slowly (1 acquisition/C) increasing the
temperature up to 95C and continuously measuring the
fluorescence intensity. The results of melting curve anal-
ysis have been confirmed by analyzing two patient sam-
ples for each possible genotype using sequence analysis.
For sequencing, the total volume of the PCR was 100ml
containing 250 ng of genomic DNA, 1PCR-buffer
(Qiagen, Hilden, Germany), the final MgCl2
concentration as given in Table 2B, 0.2mM of a
dNTP-Mix (Sigma, Steinheim, Germany), 2.5 units of
HotStar Plus TaqTM DNA polymerase (Qiagen) and
10 pmol of each primer (TIB MOLBIOL). The PCR
comprised an initial denaturation step (95C for
5min), 35 cycles (denaturation at 94C for 30 s, primer
annealing temperature as given in Table S1 for 30 s,
extension at 72C for 30 s) and a final extension step
(72C for 10min). The PCR products were purified
using the QIAquick PCR Purification Kit (Qiagen)
and sequenced by a commercial sequencing company
(Sequiserve, Vaterstetten, Germany). All sequences of
primers and FRET probes and primer annealing tem-
peratures used for genotyping and for sequence analysis
are given in supplementary material (Tables S1 and S2).
Statistical analysis
Deviations from the Hardy–Weinberg equilibrium were
tested in the control group separately for each genetic
marker using an Exact test and a type 1 error level of
0.05.23 Statistical power analysis was performed under
the assumption that the minor allele frequency equals
at least 0.1 roughly corresponding to the lower limit for
the marker allele frequencies among control individuals
(<http://ihg2.helmholtz-muenchen.de/cgi-bin/hw/power2.
pl>). Significance of associations with or between single
locus genotypes were assessed with Fisher’s exact test
or the chi-squared test with Yates correction where
appropriate. Using Bonferroni correction for five non-
independent tests (5 SNPs), the nominal probability
value was set at P¼ 0.01. Subgroup analysis was done
according to gender, smoking and severity of disease.
For comparison of quantitative variables (i.e. age), the
Student’s t-test was used. Analysis was performed
using PASW software, v18.0 (SPSS Inc., Chicago, IL,
USA). For the determination of the mode of inheri-
tance that could best explain associations, Akaike’s
Information Criterion was used.24 Each SNP was con-
sidered under a co-dominant, dominant, recessive and
over-dominant effect model using SNPStats (<http://
bioinfo.iconcologia.net/index.php?module¼Snpstats>).
For haplotype analysis, linkage disequilibrium
Table 2. Frequency distribution of genotypes for the five polymorphisms at the PPARG locus
SNP (alleles)
Genotypes periodontitis (%) Genotypes control (%)
N 11 N 12 N 22 MAF N 11 N 12 N 22 MAF HWE
rs10865710 (C/G) 221 (55.7) 157 (39.5) 19 (4.8) 24.6 414 (53.8) 296 (38.5) 59 (7.7) 26.9 0.58
rs2067819 (G/A) 248 (62.3) 136 (34.2) 14 (3.5) 20.6 461 (59.3) 268 (34.5) 48 (6.2) 23.4 0.27
rs3892175 (G/A) 345 (86.7) 52 (13.1) 1 (0.2) 6.8 621 (80.1) 145 (18.7) 9 (1.2) 10.5 0.85
rs1801282 (C/G) 293 (73.8) 96 (24.2) 8 (2.0) 14.1 581 (75.5) 173 (22.5) 16 (2.0) 13.3 0.44
rs3856806 (C/T) 295 (74.5) 97 (24.5) 4 (1.0) 13.3 561 (72.3) 193 (24.9) 22 (2.8) 15.3 0.27
N, number of individuals; 1, major allele; 2, minor allele; MAF, minor allele frequency; HWE, analysis of Hardy–Weinberg equilibrium.
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measures were estimated from inferred haplotypes
using the Haploview v4.2 software.25 Haplotype fre-
quencies were estimated with the expectation maxima-
tion algorithm.26 Analysis of associations between
haplotypes and phenotypes was performed with
SNPStats after adjustment for age, gender, and smok-
ing as confounding variables using logistic regression.
Since 3-site haplotypes have been used for this analysis,
the level of significance was set at P< 0.017 after
Bonferroni correction.
Results
Study sample
A total of 402 patients with chronic periodontitis and
793 healthy control individuals have been genotyped
for the five polymorphisms at the human PPARG
locus. The power calculation revealed that the mini-
mum sample size for patients with periodontitis
required 383 individuals and 778 for the healthy
controls.
Frequency distribution of alleles and genotypes
Minor allele and genotype frequencies of the five poly-
morphisms of the peroxisome proliferator-activated
receptor PPARG gene within both study groups are
shown in Table 2. For each SNP, the genotype frequen-
cies were in agreement with the Hardy–Weinberg
equilibrium.
The minor allele frequencies for the five SNPs varied
between 6.8% and 24.6% in the periodontitis group
and between 10.5% and 26.9% in the control popula-
tion. Considering different effect models with Akaike’s
Information Criterion showed that a recessive model
does best fit to the data as observed herein. Doing asso-
ciation analysis under a recessive effect model after
adjustment for age, gender, and smoking revealed an
obviously significant association for the polymorphism
rs3856806 (P¼ 0.04). The mutant allele was more prev-
alent among healthy individuals (rs3856806 T allele:
15.3%) than in periodontitis patients (rs3856806 T
allele: 13.3%; Table 3). However, after performing
Bonferroni correction for multiple testing, this associa-
tion remained non-significant. Also, subclass analysis
according to gender and smoking revealed no nominal
significant association between any of the tested poly-
morphisms and periodontal disease (supplementary
Table S3).
Linkage disequilibrium and haplotype analysis
Linkage disequilibrium between the five tested loci is
given as Lewontin’s D’ in Table 4. Two SNPs
(rs10865710 and rs3892175) were in strong LD with
rs2067819 (D’> 0.9). A 3-site haplotype analysis
excluding rs10865710 and rs3892175 revealed a fre-
quency of 1% for a total of five haplotypes in both
study groups (Table 5). Three of these haplotypes com-
posed of rs2067819, rs1801282 and rs3856806
seemed to be significantly associated with periodontitis
(A-G-C: P¼ 0.019; OR 0.44, 95% CI 0.22–0.87;
Table 3. Analysis of associations between single locus genotypes for the five polymorphisms at the PPARG locus with periodontitis
using five different effect models, i.e. co-dominant, dominant, recessive, and over-dominant
rs10865710 rs2067819 rs3892175 rs1801282 rs3856806
Co-dominant model
P-value 0.32 0.63 0.07 0.75 0.07
ORhet (95% CI) 0.96 (0.69–1.32) 0.99 (0.71–1.36) 1.31 (0.86–1.99) 0.87 (0.60–1.25) 1.19 (0.84–1.69)
ORhom (95% CI) 1.59 (0.82–3.09) 0.96 (0.66–3.08) NA 0.99 (0.32–3.05) 4.15 (0.99–17.47)
AIC 980.4 991 984.6 982.5 981.6
Dominant model
P-value 0.82 0.86 0.13 0.47 0.17
OR (95% CI) 1.03 (0.75–1.40) 1.03 (0.75–1.40) 1.37 (0.91–2.08) 0.88 (0.62–1.25) 1.28 (0.90–1.80)
AIC 980.6 989.9 985.6 980.5 982.9
Recessive model
P-value 0.14 0.34 0.06 0.98 0.04
OR (95% CI) 1.62 (0.84–3.10) 1.44 (0.67–3.07) NA 1.02 (0.33–3.14) 3.96 (0.94–16.61)
AIC 978.4 989 984.2 981 980.5
Over-dominant model
P-value 0.56 0.81 0.22 0.45 0.42
OR (95% CI) 0.91 (0.67–1.25) 0.96 (0.70–1.32) 1.29 (0.85–1.96) 0.87 (0.60–1.25) 1.15 (0.81–1.64)
AIC 980.3 989.9 986.4 980.5 984.2
Results obtained following adjustment for smoking, gender, and age. OR, odds ratio; ORhet, odds ratio for the heterozygote carriership of the rare
allele; ORhom, odds ratio for the homozygote carriership of the rare allele, 95% CI, confidence interval at 95%; AIC, Akaike’s Information Criterion.
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G-C-T: P¼ 0.028, OR 1.91, 95% CI 1.07–3.41; A-C-C:
P¼ 0.046; OR: 1.53, 95% CI 1.01–2.32). However,
none of these associations reached the level of nominal
significance after Bonferroni correction (P< 0.017).
Discussion
For the delineation of the genetic background of
chronic periodontitis directly, population-based associ-
ation studies on genetic variants affecting the regulation
of innate immunity seem to be particularly attractive.27
Peroxisome proliferator-activated receptor g was sug-
gested to have regulatory functions in innate immune
response. Recent data suggest that activators of
PPARg, e.g. thiazolidinediones, can down-modulate
inflammatory processes. So far, the expression of
PPARg has been confirmed in human osteoclasts28
and keratinocytes29 of the oral mucosa both of which
are involved in the manifestation and perpetuation of
periodontitis. Thus, it seems reasonable to assume that
PPARg might contribute to the susceptibility for peri-
odontitis. The potential role of PPARg in the patho-
genesis of periodontitis is further supported by findings
in animal studies. In rodents, exogenous PPARg
ligands, i.e. glitazones, were able to reduce the manifes-
tation of experimental periodontitis effectively.30 The
results of in vitro experiments suggest that, upon acti-
vation, PPARg inhibits RANKL-mediated osteoclasto-
genesis ultimately leading to the attenuation of
periodontal tissue destruction.31
Based on recent data, the PPARG variant rs1801282
could be of particular interest since it seemed to be asso-
ciated with the risk for periodontitis in pregnant
women.32 Pregnant carriers of the rare rs1801282-G
allele have a significantly higher susceptibility for peri-
odontal attachment loss as compared to carriers of the
wild-type allele. Although a slightly higher prevalence of
the mutant allele was found among periodontitis
patients than in healthy control subjects in the present
study, this difference did not reach significance. Also the
variant rs3856806 justifies specific interest in the context
of our study, since it was shown to be associated with
Crohn’s disease.17 It was hypothesized that periodontitis
and Crohn’s disease share a common immunopathoge-
netic pathway.33 The rare allelic variant seems to be
linked to an attenuated inflammatory response in con-
sequence lowering the individual susceptibility for
Crohn’s disease. Also, among periodontitis patients,
the rare variant was more common as compared with
healthy controls, but statistical analysis did not confirm
a significant difference between cases and controls.
As in other complex diseases, genetic association
studies in periodontitis are difficult to design since mul-
tiple genetic factors and, in addition, various pheno-
typic factors are thought to have impact on the
pathogenesis. A particular challenge is to take into
account all established risk factors for chronic peri-
odontitis. Herein, we could include at least smoking
and gender into multivariate statistical analysis.
Moreover, certain phenotypic variables might have
caused stratification of the study sample. In this respect
the influence of vascular diseases might be of particular
importance. It has been shown that the PPARG poly-
morphisms tested in this study are associated with cor-
onary heart disease and arterial hypertension.18,34 Since
no data were available on the disease status of the study
Table 5. Frequency estimates for the 3-site haplotypes composed of the genotypes for rs2067819, rs1801282 and rs3856806
Estimated frequencies
Periodontitis Controls Cumulative OR (95% CI) P-value
G-C-C 0.7475 0.6877 0.7088 1.00 NA
A-C-C 0.0712 0.1115 0.8059 1.53 (1.01–2.32) 0.04
A-G-T 0.0886 0.0796 0.8886 1.05 (0.70–1.59) 0.80
G-C-T 0.0397 0.0511 0.9353 1.91 (1.07–3.41) 0.03
A-G-C 0.0461 0.0277 0.9696 0.44 (0.22–0.87) 0.02
Association analysis was performed for the haplotypes with an estimated frequency of 1%. OR, odds ratio; 95% CI, confidence interval at 95%.
Table 4. Linkage analysis for the five polymorphisms at the PPARG locus given as Lewontins D’ value for multiple comparisons
rs10865710 rs2067819 rs3892175 rs1801282 rs3856806
rs10865710 – 0.9009 0.8863 0.8505 0.6823
rs2067819 – – 0.9314 0.8139 0.5325
rs3892175 – – – 0.6759 0.8363
rs1801282 – – – – 0.5877
rs3856806 – – – – –
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subjects considering both entities, the present findings
could not be adjusted for these potentially confounding
variables.
Although power analysis revealed that the study
sample has enough power to detect associations
between periodontitis and the genetic variants of the
PPARG locus, it might drop considerably if the relative
risk for heterozygous or homozygous carriers of a func-
tional variant that leads to periodontitis is smaller than
assumed in power calculation. For example, the C to T
transition of the polymorphism rs3856806 is a silent
mutation. One can assume that this polymorphism
showing differences in allele frequencies between both
study groups is in linkage disequilibrium to a further,
yet unknown, functional variant that ultimately leads
to an impaired immunological reaction in periodontitis.
Moreover, it was hypothesized that probably more
than 20 genetic loci contribute to the heritability of
chronic periodontitis, all of which might show only
very low penetrance.35 As previously done in other
complex genetic disorders, a genome-wide association
study probably comprises a more suitable approach to
delineate those genetic regions that are in fact involved
in the pathogenesis of periodontal disease.36
Conclusions
The findings of the present study reject the hypothesis
that variants of the human PPARG gene have impact
on the pathogenesis of chronic periodontitis.
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